These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 27215381)

  • 1. Calpain Genetic Disruption and HSP90 Inhibition Combine To Attenuate Mammary Tumorigenesis.
    Grieve S; Gao Y; Hall C; Hu J; Greer PA
    Mol Cell Biol; 2016 Aug; 36(15):2078-88. PubMed ID: 27215381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Suppression Efficacy of Heat Shock Protein 90 Inhibitor 17AAG in a Liposarcoma Mouse Model.
    Nam S; Kim H; Hong D; Park JB; Kim SJ
    Anticancer Res; 2017 Nov; 37(11):6291-6302. PubMed ID: 29061812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
    Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
    J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mesoporous silica nanoparticles co‑loading with 17‑AAG and Torin2 on anaplastic thyroid carcinoma by targeting VEGFR2.
    Wang C; Zhang R; Tan J; Meng Z; Zhang Y; Li N; Wang H; Chang J; Wang R
    Oncol Rep; 2020 May; 43(5):1491-1502. PubMed ID: 32323855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of inhibitory effects of 17-AAG nanoparticles and free 17-AAG on HSP90 gene expression in breast cancer.
    Ghalhar MG; Akbarzadeh A; Rahmati M; Mellatyar H; Dariushnejad H; Zarghami N; Barkhordari A
    Asian Pac J Cancer Prev; 2014; 15(17):7113-8. PubMed ID: 25227799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
    Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
    Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.
    Hirakawa H; Fujisawa H; Masaoka A; Noguchi M; Hirayama R; Takahashi M; Fujimori A; Okayasu R
    Cancer Med; 2015 Mar; 4(3):426-36. PubMed ID: 25582113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular signature of response and potential pathways related to resistance to the HSP90 inhibitor, 17AAG, in breast cancer.
    Zajac M; Gomez G; Benitez J; Martínez-Delgado B
    BMC Med Genomics; 2010 Oct; 3():44. PubMed ID: 20920318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 17‑AAG synergizes with Belinostat to exhibit a negative effect on the proliferation and invasion of MDA‑MB‑231 breast cancer cells.
    Zuo Y; Xu H; Chen Z; Xiong F; Zhang B; Chen K; Jiang H; Luo C; Zhang H
    Oncol Rep; 2020 Jun; 43(6):1928-1944. PubMed ID: 32236631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered molecular pathways decides the treatment outcome of Hsp90 inhibitors against breast cancer cells.
    Vykuntham NG; Suran S; Siripini S; John S; Kumar P; Paithankar K; Amere Subbarao S
    Toxicol In Vitro; 2020 Jun; 65():104828. PubMed ID: 32184171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP27 expression levels are associated with the sensitivity of hepatocellular carcinoma cells to 17-allylamino-17-demethoxygeldanamycin.
    Cui Y; Wu W; Zhou Y; Xie Q; Liu T; Jin J; Liu K
    Future Oncol; 2013 Mar; 9(3):411-8. PubMed ID: 23469976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells.
    Roforth MM; Tan C
    Anticancer Drugs; 2008 Aug; 19(7):681-8. PubMed ID: 18594209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
    Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
    Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
    Schwock J; Dhani N; Cao MP; Zheng J; Clarkson R; Radulovich N; Navab R; Horn LC; Hedley DW
    Cancer Res; 2009 Jun; 69(11):4750-9. PubMed ID: 19458065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
    Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L
    Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
    Karkoulis PK; Stravopodis DJ; Voutsinas GE
    Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
    Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
    Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.